SCHEMBL5115337

SCHEMBL5115337

COC(=O)[C@H](Cc1ccc2oc(=O)cc(C)c2c1)NC(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA9 Q16790 1/20 0.49
KLK5 Q9Y337 1/20 0.46
ALDH1A1 P00352 12/20 0.45
KDM4E B2RXH2 12/20 0.45
HSD17B10 Q99714 6/20 0.45
EPHX2 P34913 1/20 0.44
KMT2A Q03164 1/20 0.43
ALDH2 P05091 1/20 0.43
HPGD P15428 9/20 0.42
MAPT P10636 4/20 0.42
TSHR P16473 2/20 0.42
HTT P42858 2/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CTSB P07858 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115343 1.00 CA12 (0.49) CA12CA1CA9KLK5ALDH1A1
SCHEMBL10099995 0.80 KLK5 (0.55) KLK5CTSBCTSSCTSK
SCHEMBL17933019 0.80 KLK5 (0.55) KLK5CTSBCTSSCTSK
SCHEMBL7962457 0.79 KLK5 (0.53) KLK5EPHX2KMT2ACTSBCTSS
SCHEMBL7962462 0.79 KLK5 (0.53) KLK5EPHX2KMT2ACTSBCTSS
SCHEMBL8300244 0.78 KLK5 (0.53) KLK5CTSBCTSSCTSK
SCHEMBL10099992 0.78 KLK5 (0.53) KLK5CTSBCTSSCTSK
SCHEMBL10042354 0.77 KLK5 (0.52) KLK5CTSBCTSSCTSK
SCHEMBL30958049 0.77 KLK5 (0.52) KLK5CTSBCTSSCTSK
SCHEMBL30958037 0.77 KLK5 (0.52) KLK5CTSBCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439258-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2008-10-21 US disclosed
US-7439258-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2008-10-21 US disclosed
US-7439258-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD (CA) 2008-10-21 US disclosed
EP-1301487-B1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM CA LTD (CA) 2006-11-22 EP disclosed
US-20040224955-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-11-11 US disclosed
US-6794404-B2 BENZIMIDAZOLE DERIVATIVES BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-09-21 US disclosed
US-20030232816-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2003-12-18 US disclosed
US-6479508-B1 INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-11-12 US disclosed
US-6448281-B1 INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232816-A1 Viral polymerase inhibitors POLR2H, POLR2E, POLM CA12 3997/4885CA1 3775/4885CA9 2346/4885
US-20040224955-A1 Viral polymerase inhibitors POLR2H, POLR2E, POLM CA12 3997/4885CA1 3775/4885CA9 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.